| Ημερομηνία | barcode | code | περιεχομενο | τιμή παραγωγός | χονδρική | λιανική |
|---|---|---|---|---|---|---|
| 05/2018 | 2803078001010 | 307800101 | VALSART/HEREMCO F.C.TAB 80MG/TAB BTx28 | 3.21 | 3.37 | 4.64 |
| 05/2018 | 2803078001027 | 307800102 | VALSART/HEREMCO F.C.TAB 80MG/TAB BTx14 | 02.05 | 2.15 | 2.97 |
| 05/2018 | 2803078001034 | 307800103 | VALSART/HEREMCO F.C.TAB 80MG/TAB BTx30 | 3.48 | 3.65 | 05.04 |
| 05/2018 | 2803078002017 | 307800201 | VALSART/HEREMCO F.C.TAB 160MG/TAB BTx28 | 4.00 | 4.20 | 5.79 |
| 05/2018 | 2803078002024 | 307800202 | VALSART/HEREMCO F.C.TAB 160MG/TAB BTx14 | 2.21 | 2.32 | 3.20 |
| 05/2018 | 2803078002031 | 307800203 | VALSART/HEREMCO F.C.TAB 160MG/TAB BTx30 | 3.92 | 4.11 | 5.66 |
| 05/2018 | 2803078003014 | 307800301 | VALSART/HEREMCO F.C.TAB 320MG/TAB BTx28 | 6.23 | 6.53 | 9.00 |
| 05/2018 | 2803078003021 | 307800302 | VALSART/HEREMCO F.C.TAB 320MG/TAB BTx14 | 3.54 | 3.71 | 5.11 |
| 05/2018 | 2803078003038 | 307800303 | VALSART/HEREMCO F.C.TAB 320MG/TAB BTx30 | 6.67 | 7.00 | 9.65 |
For the treatment of hypertension.
Valsartan competes with angiotensin II for binding at the AT<sub>1</sub> receptor subtype. As angiotensin II is a vasoconstrictor which also stimulates the synthesis and release of aldosterone, blockage of its effects results in a decreases in systemic vascular resistance.
Absolute bioavailability = 23% with high variability
The initial phase t<sub>1/2 &alpha;</sub> is < 1 hour while the terminal phase t<sub>1/2 &beta;</sub> is 5-9 hours.
* 17 L
* 2 L/h [IV administration] * 4.5 L/h [heart Failure patients receiving oral administration 40 to 160 mg twice a day]